% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Fiedler:275758,
author = {T. Fiedler$^*$ and R. Fairless$^*$ and K. Pichi$^*$ and R.
Fischer and F. Richter and R. E. Kontermann and K.
Pfizenmaier and R. Diem$^*$ and S. Williams$^*$},
title = {{C}o-modulation of {TNFR}1 and {TNFR}2 in an animal model
of multiple sclerosis.},
journal = {Journal of neuroinflammation},
volume = {20},
number = {1},
issn = {1742-2094},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2023-00857},
pages = {100},
year = {2023},
note = {#EA:B320#LA:B320#},
abstract = {Tumour necrosis factor (TNF) is a pleiotropic cytokine and
master regulator of the immune system. It acts through two
receptors resulting in often opposing biological effects,
which may explain the lack of therapeutic potential obtained
so far in multiple sclerosis (MS) with non-receptor-specific
anti-TNF therapeutics. Under neuroinflammatory conditions,
such as MS, TNF receptor-1 (TNFR1) is believed to mediate
the pro-inflammatory activities associated with TNF, whereas
TNF receptor-2 (TNFR2) may instead induce anti-inflammatory
effects as well as promote remyelination and
neuroprotection. In this study, we have investigated the
therapeutic potential of blocking TNFR1 whilst
simultaneously stimulating TNFR2 in a mouse model of
MS.Experimental autoimmune encephalomyelitis (EAE) was
induced with myelin oligodendrocyte glycoprotein (MOG35-55)
in humanized TNFR1 knock-in mice. These were treated with a
human-specific TNFR1-selective antagonistic antibody (H398)
and a mouse-specific TNFR2 agonist (EHD2-sc-mTNFR2), both in
combination and individually. Histopathological analysis of
spinal cords was performed to investigate demyelination and
inflammatory infiltration, as well as axonal and neuronal
degeneration. Retinas were examined for any protective
effects on retinal ganglion cell (RGC) degeneration and
neuroprotective signalling pathways analysed by Western
blotting.TNFR modulation successfully ameliorated symptoms
of EAE and reduced demyelination, inflammatory infiltration
and axonal degeneration. Furthermore, the combinatorial
approach of blocking TNFR1 and stimulating TNFR2 signalling
increased RGC survival and promoted the phosphorylation of
Akt and NF-κB, both known to mediate neuroprotection.These
results further support the potential of regulating the
balance of TNFR signalling, through the co-modulation of
TNFR1 and TNFR2 activity, as a novel therapeutic approach in
treating inflammatory demyelinating disease.},
keywords = {EAE (Other) / Neuroinflammation (Other) / Neuroprotection
(Other) / TNFR1 (Other) / TNFR2 (Other)},
cin = {B320 / HD01},
ddc = {610},
cid = {I:(DE-He78)B320-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37122019},
doi = {10.1186/s12974-023-02784-z},
url = {https://inrepo02.dkfz.de/record/275758},
}